Seminars in Oncology
Volume 34, Issue 2 , Pages 85-97 , April 2007

Advances in the Management of Superficial Bladder Cancer

  • Michael A. O’Donnell

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael A. O’Donnell, MD, FACS, 200 Hawkins Dr, 3RCP, Iowa City, IA 52242.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43–66
  2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2006;55:74–108
  3. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–1330
  4. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005;66(suppl 1):4–34
  5. Travis LB, Curtis RE, Glimelius B. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1995;87:524–530
  6. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686–1692
  7. Karagas MR, Tosteson TD, Morris JS, et al. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control. 2004;15:465–472
  8. Weyer PJ, Cerhan JR, Kross BC, et al. Municipal drinking water nitrate level and cancer risk in older women: The Iowa Women’s Health Study. Epidemiology. 2001;12:327–338
  9. Aben KK, Witjes JA, Schoenberg MP, et al. Familial aggregation of urothelial cell carcinoma. Int J Cancer. 2002;98:274–278
  10. Kiemeney LA, Kuiper RP, Pfundt R, et al. No evidence for large-scale germline genomic aberrations in hereditary bladder cancer patients with high-resolution array-based comparative genomic hybridization. Cancer Epidemiol Biomarkers Prev. 2006;15:180–183
  11. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649–659
  12. Grignon DJ, Shum DT, Bruckschwaiger O. Transitional cell carcinoma in the Muir-Torre syndrome. J Urol. 1987;138:406–408
  13. O’Donnell MA, Lilli K, Leopold C. Contemporary profile of superficial bladder cancer revealed from an open-entry national multicenter study. J Urol. 2004;171(suppl):283A;(abstr)
  14. Wijkstrom H, Cohen SM, Gardiner RA, et al. Prevention and treatment of urothelial premalignant and malignant lesions. Scand J Urol Nephrol. 2000;205(suppl):116–135
  15. Bassi P, De Marco V, De Lisa A, et al. Non-invasive diagnostic tests for bladder cancer: A review of the literature. Urol Int. 2005;75:193–200
  16. Amiel GE, Shu T, Lerner SP. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr Treat Options Oncol. 2004;5:377–389
  17. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810–816
  18. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299–305
  19. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. Urol. 2002;167:80–83
  20. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol. 2005;47:736–748
  21. Glas AS, Roos D, Deutekom M, et al. Tumor markers in the diagnosis of primary bladder cancer (A systematic review). J Urol. 2003;169:1975–1982
  22. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analysis. Urology. 2003;61:109–118
  23. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285:324–328
  24. Sanchini MA, Gunelli R, Bravaccini S, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294:2052–2056
  25. Sorensen FB, Sasaki M, Fukuzawa S, et al. Qualitative and quantitative histopathology in transitional cell carcinomas of the urinary bladder (An international investigation of intra- and interobserver reproducibility). Lab Invest. 1994;70:242–254
  26. Heney NM. Natural history of superficial bladder cancer: Prognostic features and long-term disease course. Urol Clin North Am. 1992;19:429–433
  27. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder cancer. Eur J Cancer. 1995;31A:1840–1846
  28. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466
  29. Holmang S, Hedelin H, Anderstrom C, et al. The relationship among multiple recurrences, progression and prognosis in patients with stage Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol. 1995;153:1823–1827
  30. Fitzpatrick JM, West AB, Butler MR. Superficial bladder tumors: The importance of recurrence pattern following initial resection. J Urol. 1986;135:920–924
  31. Williams SG, Buscarini M, Stein JP. Molecular markers for diagnosis, staging, and prognosis of bladder cancer. Oncology. 2001;15:1461–1470
  32. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?. J Urol. 2001;165:808–810
  33. Jakse G, Algaba F, Malmstrom PU, et al. A second-look TUR in T1 transitional cell carcinoma: Why?. Eur Urol. 2004;45:539–546
  34. Sanchez-Chapado M, Angulo JC, Hontoria H, et al. [Staging error in bladder carcinoma: Anatomo-clinical correlation]. Actas Urol Esp. 1995;19:32–39
  35. Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in non-muscle invasive micropapillary transitional cell carcinoma of the bladder. J Urol. 2005;173(suppl):915A;(abstr)
  36. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172:481–484
  37. Lee CT, Montie JE, Zhang YX, et al. Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer. J Urol. 2005;173(suppl):911A;(abstr)
  38. Lamm DL, Griffith JG. Intravesical therapy: Does it affect the natural history of superficial bladder cancer?. Semin Urol. 1992;10:39–44
  39. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol. 2005;174:862–866
  40. Riedl CR, Daniltchenko D, Koenig F, et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol. 2001;165:1121–1123
  41. Babjuk M, Soukup V, Petrik R, et al. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96:798–802
  42. Filbeck T, Roessler W, Knuechel R, et al. 5-Aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology. 1999;53:77–81
  43. Trkova M, Babjuk M, Duskova J, et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Lett. 2005;242:68–76
  44. Soloway MS, Nissenkorn I, McCallum L. Urothelial susceptibility to tumor cell implantation: Comparison of cauterization with N-methyl-N-nitrosourea. Urology. 1983;21:159–161
  45. Kaasinen E, Rintala E, Hellstrom P, et al. FinnBladder Group Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42:167–174
  46. Hinotsu S, Akaza H, Ohashi Y, et al. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer. 1999;86:1818–1826
  47. Goto K, Konomoto T, Hayashi K, et al. p53 mutations in multiple urothelial carcinomas: A molecular analysis of the development of multiple carcinomas. Mod Pathol. 1997;10:428–437
  48. Traynelis CL, Lamm DL. Current status of intravesical therapy for bladder cancer. In:  Rous SN editors. Urology Annual. vol 8:New York, NY: Norton; 1994;p. 113–143
  49. Lamm DL, Riggs DR, Ttaynelis CL, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995;153:1444–1450
  50. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: Results of a meta-analysis. Anticancer Res. 2001;21:765–769
  51. O’Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am. 2005;32:121–131
  52. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am. 1992;19:529–539
  53. Bouffioux C, Denis L, Oosterlinck W, et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J Urol. 1992;148:297–301
  54. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193–3198
  55. Bartoletti R, Cai T, Gacci M, et al. TUR (Toscana Urologia) Group Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study. Urology. 2005;66:726–731
  56. McKiernan JM, Murphy AM, Goetzl M, et al. Phase I trial intravesical docetaxel (Taxotere) for recurrent superficial bladder cancer. 2005;Program and abstracts of the American Urological Association Annual Meeting, San Antonio, TX, May 21-26, (abstr 916)
  57. Sekine H, Ohya K, Kojima SI, et al. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol. 2001;8:483–486
  58. Maymi JL, Saltsgaver N, O’Donnell MA. Intravesical sequential chemotherapy for patients at high risk with refractory superficial bladder cancer. J Urol. 2006;174(suppl):271;(abstr 840)
  59. Au JL, Badalament RA, Wientjes MG, et al. International Mitomycin C Consortium Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst. 2001;93:597–604
  60. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–4276
  61. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. J Urol. 2003;170:777–782
  62. Kavoussi LR, Torrence RJ, Gillen DP, et al. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol. 1988;139:935–940
  63. Sylvester RJ, van der Meidjen AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970
  64. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90–95
  65. Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation. Am J Clin Oncol. 2003;26:402–407
  66. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int. 2004;93:485–490
  67. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63:682–686
  68. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174:86–91
  69. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol. 2000;163:1124–1129
  70. Thalmann GN, Sermier A, Rentsch C, et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol. 2000;164:2129–2133
  71. Watanabe E, Matsuyama H, Matsuda K, et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003;52:481–486
  72. Saint F, Patard JJ, Maille P, et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol. 2002;167:364–367
  73. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386–3390
  74. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23:5746-5456
  75. Lamm DL, Steg A, Boccon-Gibad L, et al. Complications of bacillus Calmette-Guerin immunotherapy: Review of 2,602 patients and comparison of chemotherapy complications. Prog Clin Biol Res. 1989;310:335
  76. Steg A, Leleu C, Debre B, et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res. 1989;310:325–334
  77. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Club Urologico Espanol de Tratamiento Oncologico (CUETO) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? (Results of a prospective randomized trial). J Urol. 2005;174:1242–1247
  78. Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol. 1995;27:19–22(suppl 1)
  79. Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol. 1992;147:1256–1258
  80. Andius P, Fehrling M, Holmang S. Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96:1290–1293
  81. Bassi P, Spinadin R, Carando R, et al. Modified induction course: A solution to side-effects?. Eur Urol. 2000;37(suppl 1):31–32
  82. Belldegrun AS, Franklin JR, O’Donnell MA, et al. Superficial bladder cancer: The role of interferon-alpha. J Urol. 1998;159:1793–1801
  83. Ficarra V, Dalpiaz O, Alrabi N, et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 2005;95:786–790
  84. May M, Helke C, Nitzke T, et al. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004;72:103–111
  85. Stein JP. Indications for early cystectomy. Urology. 2003;62:591–595
  86. Harland SJ UK NCRI Bladder Clinical Studies Group. A randomized trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06). J Clin Oncol. 2005;23:S16;(abstr 4505)
  87. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 2005;66(suppl 1):108–125
  88. Thalmann GN, Markwalder R, Shahin O, et al. Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy?. J Urol. 2004;172:70–75
  89. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol. 1989;141:22–29
  90. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137:220–224
  91. Huguet J, Crego M, Sabate S, et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005;48:53–59
  92. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology. 1997;49:687–690
  93. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48:231–238
  94. Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173:401–404
  95. Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome. J Clin Oncol. 1996;14:2646–2652
  96. Prout GR, Wesley MN, Yancik R, et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: A population-based study. Cancer. 2005;104:1638–1647
  97. Malmstrom PU, Wijkstrom H, Lundholm C, et al. Swedish-Norwegian Bladder Cancer Study Group 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1999;161:1124–1127
  98. Steinberg G, Bahnson R, Brosman S, et al. The Valrubicin Study Group Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000;163:761–767
  99. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46:65–71
  100. O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166:1300–1304
  101. Joudi FN, Smith BJ, O’Donnell MA, et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24:344–348
  102. Akcetin Z, Todorov J, Tuzel E, et al. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res. 2005;25:1623–1628
  103. Nseyo UO, Shumaker B, Klein EA, et al. Bladder Photofrin Study Group Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol. 1998;160:39–44
  104. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003;170:428–432
  105. Schwalb MD, Herr HW, Sogani PC, et al. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: Pattern of recurrence. J Urol. 1994;152:382–387
  106. Morgan JD, Bowsher W, Griffiths DF, et al. Rationalization of follow-up in patients with non-invasive bladder tumors. Br J Urol. 1993;72:135–142
  107. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer. 1999;86:2337–2345
  108. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol. 1994;151:21–26
  109. Pruthi RS, Derksen E, Gaston K, et al. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology. 2004;64:637–642
  110. Lerner SP, Sabichi AL, Grossman HB, et al. Results of a randomized chemoprevention trial with finretinide in non-muscle invasive bladder cancer. J Urol. 2005;173(suppl):913A;(abstr)
  111. Messing EM, Kim KM, Wilding G, et al. A randomized prospective phase II trial of difluoromethylornithine (DFMO) vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2005;173(suppl):922A;(abstr)

PII: S0093-7754(06)00489-1

doi: 10.1053/j.seminoncol.2006.12.012

Seminars in Oncology
Volume 34, Issue 2 , Pages 85-97 , April 2007

Article Tools

* Image Usage & Resolution